645 reports of this reaction
2.0% of all KETOCONAZOLE reports
#10 most reported adverse reaction
PSORIASIS is the #10 most commonly reported adverse reaction for KETOCONAZOLE, manufactured by Kramer Laboratories. There are 645 FDA adverse event reports linking KETOCONAZOLE to PSORIASIS. This represents approximately 2.0% of all 31,685 adverse event reports for this drug.
Patients taking KETOCONAZOLE who experience psoriasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PSORIASIS is a less commonly reported adverse event for KETOCONAZOLE, but still significant enough to appear in the safety profile.
In addition to psoriasis, the following adverse reactions have been reported for KETOCONAZOLE:
The following drugs have also been linked to psoriasis in FDA adverse event reports:
PSORIASIS has been reported as an adverse event in 645 FDA reports for KETOCONAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PSORIASIS accounts for approximately 2.0% of all adverse event reports for KETOCONAZOLE, making it a notable side effect.
If you experience psoriasis while taking KETOCONAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.